STOCK TITAN

Join 60 Degrees Pharmaceuticals' Live Investor Webinar: Advancing Tafenoquine for Babesiosis While Expanding ARAKODA(R) Commercialization

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

60 Degrees Pharmaceuticals (Nasdaq: SXTP) will participate in a RedChip investor webinar on November 10, 2026, covering tafenoquine development and commercialization. Chairman and CEO Geoff Dow will present at 4:15 p.m. ET, followed by live questions.

In March 2026, all three patients in an expanded-access study of relapsing babesiosis were reported cured following tafenoquine treatment. A separate randomized, double-blind, placebo-controlled study in hospitalized babesiosis patients reached the 24-patient minimum for interim analysis. The company had planned an interim readout by October 6, 2026, and plans to seek an FDA meeting after the analysis to discuss requirements for a potential New Drug Application. The webinar will also cover expansion initiatives for ARAKODA, its FDA-approved malaria-prevention product, including increased inside sales capacity.

Loading...
Loading translation...

Positive

  • Minor pointExpanded-access babesiosis study reported all three patients cured following tafenoquine treatment in March 2026.
  • Minor pointHospitalized babesiosis study reached the 24-patient minimum enrollment required for interim analysis.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Regulatory plans include seeking an FDA meeting after interim analysis about potential New Drug Application requirements.
  • Minor point. Forward-looking: it has not happened yet and may not happen.ARAKODA commercial expansion initiatives for 2026 include increased inside sales capacity.

Negative

  • None.

Key Figures

Patients cured: All 3 patients Minimum enrollment for interim analysis: 24 patients Interim data readout: Planned by October 6, 2026 +3 more
Patients cured
All 3 patients
Expanded-access study of relapsing babesiosis following tafenoquine treatment
Minimum enrollment for interim analysis
24 patients
Hospitalized babesiosis study; minimum enrollment reached
Interim data readout
Planned by October 6, 2026
Randomized, double-blind, placebo-controlled hospitalized babesiosis study
Addressable U.S. patients
Up to 380,000 annually
Company's initial research estimate for babesiosis
Potential peak annual sales
Up to $245 million
Company's initial estimate for babesiosis
Potential cumulative revenue
Up to $1.1 billion
Through patent expiration in 2035; company estimate

Key Terms

expanded-access study, placebo-controlled, interim analysis, new drug application
4 terms
expanded-access study regulatory
"all three patients in its expanded-access study of relapsing babesiosis"
A regulated program that allows patients with serious or life-threatening conditions to receive an investigational drug, biologic, or medical device outside a clinical trial when no approved therapies are available and the patient cannot join an ongoing trial. Expanded-access access is authorized by the product’s sponsor and by regulators (and usually reviewed by an institutional review board); it is intended to provide potential individual benefit rather than to test efficacy, so use is typically limited, subject to safety monitoring and reporting, and does not replace the controlled design and evidence standards of clinical trials.
placebo-controlled medical
"randomized, double-blind, placebo-controlled study"
"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.
interim analysis medical
"required for an interim analysis"
An interim analysis is an early review of a project or process before it is fully completed. For investors, it provides a snapshot of progress or performance, helping to identify whether things are on track, need adjustment, or should be stopped early. Think of it as a progress report that can influence decisions before the final outcome is known.
new drug application regulatory
"requirements for a potential New Drug Application submission"
A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

ORLANDO, FL / ACCESS Newswire / November 4, 2026 / RedChip Companies will host an investor webinar on Tuesday, November 10, 2026, at 4:15 p.m. ET with 60 Degrees Pharmaceuticals, Inc. (Nasdaq:SXTP).

The exclusive event will feature Geoff Dow, Chairman and CEO, who will provide an overview of 60 Degrees Pharmaceuticals' strategy to develop and commercialize therapies for vector-borne diseases. The presentation will focus on the Company's FDA-approved antimalarial ARAKODA® (tafenoquine), its commercial expansion initiatives, and the advancement of tafenoquine for babesiosis, a tick-borne infection for which there is currently no FDA-approved treatment specifically for the disease.

Dow will discuss the Company's clinical progress in babesiosis. In March 2026, 60 Degrees Pharmaceuticals reported that all three patients in its expanded-access study of relapsing babesiosis were cured following tafenoquine treatment. The Company has also reached the minimum 24-patient enrollment required for an interim analysis of its randomized, double-blind, placebo-controlled study in hospitalized babesiosis patients, with an interim data readout planned by October 6, 2026.

The webinar will also address the potential regulatory pathway for tafenoquine in babesiosis. Following the interim analysis, the Company plans to seek a meeting with the U.S. Food and Drug Administration to discuss the requirements for a potential New Drug Application submission. Management will discuss how the upcoming data could inform the next stage of the program.

The presentation will highlight the potential U.S. market opportunity for babesiosis. Initial Company research estimated a maximum of up to 380,000 addressable U.S. patients annually, representing up to $245 million in potential peak annual sales and up to $1.1 billion in cumulative revenue potential through patent expiration in 2035. The Company believes increasing disease incidence is being driven by the expanding geographic range of ticks and a growing immunocompromised population.

Dow will also provide an update on ARAKODA®, the Company's FDA-approved, long-acting antimalarial co-developed with the U.S. Army. ARAKODA® is commercially available in the United States through a network of major national distributors, and the Company's 2026 commercial expansion initiatives include increased inside sales capacity, enhanced digital marketing, GoodRx access, and availability through the Runway Health travel telehealth platform.

The webinar will further discuss how 60 Degrees Pharmaceuticals is leveraging an already-commercialized product, existing commercial infrastructure, and its experience with tafenoquine as it pursues additional opportunities in vector-borne disease.

A live question and answer session will follow the presentation.

To register for the free webinar, please visit: https://www.redchip.com/webinar/SXTP/83874994795

Questions can be pre-submitted to SXTP@redchip.com or online during the live event.

About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc., founded in 2010, develops and commercializes new medicines for the treatment and prevention of vector-borne disease. The Company won U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018 and currently has 3 active clinical trials underway for babesiosis, an emerging tick-borne disease. ARAKODA is sold commercially in the U.S. and Australia. 60 Degrees also collaborates with prominent research and academic organizations in the U.S. and Australia to advance science around vector-borne disease. The Company is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. Founded in 1992 as a small-cap research firm, RedChip gained early recognition for initiating coverage on emerging blue chip companies such as Apple, Starbucks, Daktronics, Winnebago, and Nike. Over the past 34 years, RedChip has evolved into a full-service investor relations and media firm, delivering concrete, measurable results for its clients, which have included U.S. Steel, Perfumania, Cidara Therapeutics, and Celsius Holdings, among others. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US and CNBC; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

Sign Up for RedChat

RedChat™ is an AI-powered investment research assistant designed to give investors instant access to critical insights from SEC filings, press releases, and corporate disclosures. Built to streamline small-cap and microcap stock research, RedChat analyzes thousands of public company documents and delivers clear, context-rich answers to investor questions in seconds. Instead of manually reviewing lengthy filings, investors can simply ask RedChat about financial results, partnerships, business strategy, or recent announcements and receive precise, source-based summaries. Investors can experience RedChat and start exploring stocks today at www.redchip.com/stocks or www.red.chat.

To learn more about RedChip's products and services, please visit: https://www.redchip.com/corporate/investor_relations

"Discovering Tomorrow's Blue Chips Today"™

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

Follow RedChip on Twitter: https://twitter.com/RedChip

Follow RedChip on YouTube: https://www.youtube.com/@redchip

Follow RedChip on Rumble: https://rumble.com/c/c-3068340

Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

Disclaimer

This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Certain statements regarding 60 Degrees Pharmaceuticals, Inc. ("60 Degrees Pharmaceuticals") and its business, commercial activities, clinical programs, anticipated data readouts, regulatory plans, market opportunity, plans and prospects may constitute forward-looking statements and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Investors should review 60 Degrees Pharmaceuticals' filings with the Securities and Exchange Commission for additional information regarding the Company and the risks associated with an investment in its securities.

RedChip Companies, Inc. provides investor relations and media services to 60 Degrees Pharmaceuticals and receives compensation for those services. Visit https://www.redchip.com/legal/disclosures for details. The information regarding 60 Degrees Pharmaceuticals contained in this release has been derived from information provided by the Company or from publicly available sources. RedChip does not independently verify all such information and makes no representation or warranty as to its accuracy or completeness. Nothing contained herein should be construed as investment advice or a recommendation to buy or sell any security.

Contact:

Dave Gentry
RedChip Companies Inc.
1-407-644-4256 | 1-800-REDCHIP (733-2447)
SXTP@redchip.com

SOURCE: RedChip Companies, Inc.



View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is the 60 Degrees Pharmaceuticals SXTP investor webinar?

The webinar is scheduled for November 10, 2026, at 4:15 p.m. ET. RedChip will host Chairman and CEO Geoff Dow for a presentation on tafenoquine development and ARAKODA commercialization, followed by a live question-and-answer session.

What babesiosis clinical progress will 60 Degrees Pharmaceuticals discuss?

The clinical update includes all three patients reported cured following tafenoquine treatment in an expanded-access study of relapsing babesiosis, reported in March 2026. A separate randomized, double-blind, placebo-controlled study in hospitalized babesiosis patients reached the minimum 24-patient enrollment required for interim analysis.

Keep reading